PU
Peking University Cancer Hospital at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Peking University Cancer Hospital takes part in 9 sessions at ESMO 2026 in Madrid. Its program centres on upper gastrointestinal cancers, from better-tolerated first-line treatment of HER2-positive gastroesophageal adenocarcinoma to personalised vaccines and cell therapies. Other sessions cover an EZH1/2 inhibitor in epithelioid sarcoma, a PD-1/VEGF bispecific antibody in kidney cancer and lessons from China-only trials.
| Organization | ESMO 2026 Attendance |
|---|---|
PU Peking University Cancer Hospital Beijing, China | |
Cancer hospital and research institute of Peking University in Beijing, China. | Abstract Fri Oct 23 17:10–17:20 Abstract Sat Oct 24 15:30–15:40 3714O - HH2853, an EZH1/2 Inhibitor, in Patients with Epithelioid Sarcoma: promising anti- tumor activity Results from the pivotal phase II (HH2853-G101 cohort 2) study Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 15:47–15:57 Talk Sat Oct 24 19:15–19:30 Presentation of a clinical case: Improving patient tolerability of first line therapeutic options Gastrointestinal cancersBiomarkers & precision oncology Abstract Sun Oct 25 09:27–09:32 Abstract Sun Oct 25 09:32–09:42 Chair Mon Oct 26 08:30–10:00 Advancing targeted and immunotherapeutic strategies in upper GI cancer Gastrointestinal cancers Talk Mon Oct 26 09:15–09:30 Personalised vaccines and cell therapies Gastrointestinal cancers Abstract Mon Oct 26 10:15–10:25 Abstract Mon Oct 26 10:25–10:35 |
Instantly find 20 buyers from Peking University Cancer Hospital
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction